
HDFC Pharma And Healthcare Fund Analyst Review: NAV, Returns and Key Insights 2026
Updated: 4 Jun 2026 • 11:04 am
Posted by:

The HDFC Pharma And Healthcare Fund Direct Growth plan has delivered a 1-year return of 20.78% and a 3-month return of 8.59%, offering investors steady exposure to its target segment. With a NAV of Rs 19.93 and AUM of Rs 2,158.58 crore, the fund maintains a solid footing in its category. This analyst review covers performance, costs, risks, and investment suitability for 2026.
Click Here – Get Mutual Fund Advisory
What Is the HDFC Pharma And Healthcare Fund?
The HDFC Pharma And Healthcare Fund is a Sectoral/Thematic equity fund concentrating its portfolio around a specific sector, industry, or investment theme. Thematic funds offer high-conviction, focused exposure that can generate outsized returns when the theme performs well but also amplifies drawdowns during adverse cycles. The fund carries a Very High risk rating and is best used as a satellite allocation within a diversified portfolio.
HDFC Pharma And Healthcare Fund NAV and AUM
The current NAV of the HDFC Pharma And Healthcare Fund Direct Growth plan is Rs 19.93. NAV is updated each trading day and reflects the closing market prices of the fund's underlying securities. Always verify the most recent NAV on the AMC website or a registered mutual fund platform before placing any transaction.
The fund manages Rs 2,158.58 crore in assets, indicating a healthy investor base with meaningful conviction in its investment approach and adequate liquidity for most investor needs. Investors should track AUM trends alongside performance metrics when evaluating this fund.
HDFC Pharma And Healthcare Fund Returns: Performance Snapshot
| Period | Returns |
|---|---|
| 1 Month | 8.74% |
| 3 Months | 8.59% |
| 1 Year | 20.78% |
| 3 Years (Annualised) | Not Available |
| 5 Years (Annualised) | Not Available |
The HDFC Pharma And Healthcare Fund has delivered a 1-year return of 20.78% and a 3-month return of 8.59%, reflecting steady conditions in the underlying market segment. While these numbers may appear modest, consistent compounding at this rate over 5 to 7 years can produce meaningful portfolio growth. Investors should compare returns against the fund's benchmark and category average before drawing conclusions.
Expense Ratio and Cost Efficiency
The HDFC Pharma And Healthcare Fund Direct Growth plan carries an expense ratio of 0.87% per annum, in line with the average for actively managed funds in its category. This expense level reflects the cost of professional portfolio management. Investors should weigh this cost against the fund's performance consistency and risk-adjusted returns when making their evaluation.
Who Should Invest in HDFC Pharma And Healthcare Fund?
The HDFC Pharma And Healthcare Fund suits investors with high conviction in the specific sector or theme the fund targets, combined with a Very High risk appetite and a minimum 5 to 7-year horizon. The minimum SIP is Rs 100 and minimum lumpsum is Rs 100. Thematic funds should be used as satellite allocations of 10 to 15 percent rather than as core holdings. Investors without a specific view on the underlying theme should avoid this fund.
Key Risks to Consider
Concentration Risk: Thematic funds invest in a narrow market segment. A structural or cyclical downturn in the specific sector or theme provides limited diversification away from the adverse impact.
Timing Risk: Entry at peak valuations during a theme's popularity can result in extended periods of underperformance. Thematic funds are highly sensitive to investor entry and exit timing.
Regulatory Risk: Sectors such as defence, pharma, and energy can be significantly impacted by government policy changes or regulatory shifts that are difficult to predict in advance.
Valuation Risk: Elevated valuations in the underlying investment universe can reduce future return potential even if the fundamental business performance of portfolio companies remains strong.
Download the Univest iOS App or Univest Android App to track this fund's live NAV and manage your portfolio.
Conclusion
The HDFC Pharma And Healthcare Fund has delivered steady returns within its investment category. With an expense ratio of 0.87% and an AUM of Rs 2,158.58 crore, it offers a structured route to its target market segment. Investors with a long-term horizon who believe in the fund's mandate should ensure it aligns with their overall portfolio strategy. Consult a SEBI-registered investment advisor before investing.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Frequently Asked Questions
What is the current NAV of HDFC Pharma And Healthcare Fund?
Ans. The current NAV of the HDFC Pharma And Healthcare Fund Direct Growth plan is Rs 19.93. NAV is updated each trading day and reflects the closing market value of the fund's underlying holdings. Always verify the most recent NAV on the AMC website or a SEBI-registered mutual fund platform before transacting.
What are the returns of HDFC Pharma And Healthcare Fund?
Ans. The fund has delivered a 1-year return of 20.78% and a 3-month return of 8.59%. The 3-year annualised return is Not Available and the 5-year annualised return is Not Available. Past performance does not guarantee future results and should be evaluated alongside the fund's risk profile and benchmark comparison.
What is the expense ratio of HDFC Pharma And Healthcare Fund Direct Growth?
Ans. The expense ratio of the HDFC Pharma And Healthcare Fund Direct Growth plan is 0.87% per annum. The direct plan eliminates distributor commissions and is more cost-efficient than the regular plan. Investors should always opt for the direct plan to maximise long-term net returns through the compounding advantage of lower costs.
Is this fund suitable for conservative investors?
Ans. No. This fund carries a Very High risk rating due to concentrated exposure to a specific market segment or investment theme. It is not suitable for conservative investors or those with short investment timelines. A minimum 5 to 7-year horizon and a high risk tolerance are required prerequisites. Consult a SEBI-registered investment advisor before investing.
What is the minimum SIP amount for this fund?
Ans. The minimum monthly SIP is Rs 100 and the minimum lumpsum investment is Rs 100. The low entry thresholds make the fund accessible across income levels. A regular SIP approach is recommended to average out entry costs over time, particularly given the high-volatility nature of this fund's category.
What category and sub-category does this fund belong to?
Ans. This fund is a Sectoral/Thematic equity fund with a focused portfolio aligned to a specific sector or theme. It falls under the Sectoral / Thematic sub-category and is available as a direct growth plan, which eliminates distributor commissions and typically offers superior net returns compared to the regular plan.
Recent Articles

Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
18 November 2026

V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
18 November 2026

Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
18 November 2026

Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
Mahanadi Coalfields IPO Opens 19 November: Rs 129 to Rs 136 Price Band, Rs 8,981 Crore Offer for Sale and a Coal India Unit Valued at About 8.4 Times Earnings

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





